Abstract
Backgroud and aims: Although the bone protective effect of vitamin D has been studied intensively, the usefulness of 1,25(OH)2D3 in treating osteoporosis is still questionable. The aim of the present prospective study was to evaluate the effect of a standard pharmacological dose of 1,25(OH)2D3 in post-menopausal unsubstituted women. Methods: Our study group comprised 52 post-menopausal women with low normal or osteopenic values of bone mineral density (BMD). Thirty-two of them were treated with 1,25(OH)2D3 for 3 years. In parallel, another group of women was treated with cholecalciferol (n=20). Vitamin D adequacy before administration of 1,25(OH)2D3 and compliance with treatment were checked by serum PTH levels, which were assessed at the start and three times in the course of treatment. Results: Increase in BMD at the spine at the end of the 1st, 2nd and 3rd years of treatment with 1,25(OH)2D3 (expressed as a percentage of the value before treatment) was higher, but did not significantly differ from the effect of plain vitamin D. A significant increase in BMD at the hip at the end of the 3rd (but not the 1st and 2nd) year of treatment with 1,25(OH)2D3 was found (p<0.05, compared with the effect of plain vitamin D). The protective effect of cholecalciferol was found only on spine but not hip BMD. Conclusion: The study supports the hypothesis that long-term administration of 1,25(OH)2D3 is effective in treating low bone mass in post-menopausal women.
Similar content being viewed by others
References
Lee CJ, Lawler GS, Johnson GH. Effect of supplementation of the diets with calcium and calcium-rich foods on bone density of elderly females with osteoporosis. Am J Clin Nutr 1981; 34: 819–23.
Smith EL Jr. Reddan W, Smith PE. Physical activity and calcium modalities for bone mineral increase in aged women. Med Sci Sports Exerc 1981; 13: 60–4.
McKenna MJ, Freaney R, Meade A, Muldowney FP. Hypovitaminosis D and elevated serum alkaline phosphatase in elderly Irish people. Am J Clin Nutr 1985; 41: 101–9.
Lips P, Wiersunga A, van Ginkel FC, et al. The effect of vitamin D supplementation on vitamin D status and parathyroid function in elderly subjects. J Clin Endocrinol Metab 1988; 67: 644–50.
Himmelstein S, Clemens TL, Rubin A, Lindsay R. Vitamin D supplementation in elderly nursing home residents increases 25(OH)D but not 1,25(OH)2D. Am J Clin Nutr 1990; 52: 701–6.
Francis RM, Boyle IT, Moniz C, et al. A comparison of the effects of alfacalcidiol treatment and vitamin D2 supplementation on calcium absorption in elderly women with vertebral fractures. Osteoporos Int 1996; 6: 284–90.
Eastel R, Riggs BL. Vitamin D and osteoporosis. In: Feldman D, Glorieux FH. Pike JW. eds. Vitamin D. San Diego: Academic Press, 1997: 695–711.
Nishi Y. Rationale for active vitamin D and analogs in the treatment of osteoporosis. J Cell Biochem 2003; 88: 381–6.
Suda T. Ueno Y. Fujii K. Shinki T. Vitamin D and bone. J Cell Biochem 2003; 88: 259–66.
Takashu H, Sugita A, Uchiyama Y, et al. c-Fos protein as a target of anti-osteoclastogenic action of vitamin D, and synthesis of new analogs. J Clin Invest 2006; 116: 528–35.
Inanir A, Ozoran K, Tutkak H, Mermerci B. The effects of calcitriol therapy on serum interleukin-1, interleukin-6 and tumor necrosis factor-alpha concentrations in post-menopausal patients with osteoporosis. J Int Med Res 2004; 32: 570–82.
Iwamoto J, Seki A, Takeda T, et al. Comparative effects of risedronate and calcitriol on cancellous bone in rats with glucocorticoid-induced osteopenia. J Nutr Sci Vitaminol (Tokyo) 2006; 52: 21–7.
Need AG, Nordin C, Horowitz M, Morris HA. Calcium and calcitiol therapy in osteoporotic postmenopausal women with impaired calcium absorption. Metabolism 1990; 39: 53–4.
Zofkova I, Kancheva R. The effect of 1,25(OH)2 vitamin D3 on circulating insulin-like growth factor I and beta 2 microglobulin in patients with osteoporosis. Calcif Tissue Int 1997; 60: 236–9.
Lau KHW, Baylink DJ. Vitamin D therapy of osteoporosis: plain vitamin D therapy versus active vitamin D analog (D-hormone) therapy. Calcif Tissue Int 1999; 65: 295–306.
Weber K, Kaschig C, Erben RG. 1 Alpha-hydroxyvitamin D-2 and 1 alpha-hydroxyvitamin D-3 have anabolic effects on cortical bone, but induce intracortical remodeling at toxic doses in ovariectomized rats. Bone 2004; 35: 704–10.
Duque G, Macoritto M, Dion N, SteMarie LG, Kremer R. 1,25(OH)(2)D-3 acts as a bone-forming agent in the hormone-independent senescence-accelerated mouse (SAM-P/6). Am J Physiol — Endocrinol Metab 2005; 288: E723–30.
Del Pino-Montes J, Benito GE, Fernandez Salazar MP, et al. Calcitriol improves streptozotocin-induced diabetes and recovers bone mineral density in diabetic rats. Calcif Tissue Int 2004; 75: 526–32.
Visser M, Deeg DJ, Lips P. Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): the Longitudinal Aging Study Amsterdam. J Clin Endocrinol Metab 2003; 88: 5766–72.
Bischoff HA, Borchers M, Gudat F, et al. In situ detection of 1,25-dihydroxyvitamin D3 receptor in human skeletal muscle tissue. Histochem J 2001; 33: 19–24.
Aloia JF, Arunabh Talwar S, Polack S, Yeh J. A randomized controlled trial of vitamin D3 supplementation in African American women. Arch Intern Med 2005; 165: 1618–23.
Aloia F, Vaswani A, Yeh JK, Ellis K, Yasumura S, Cohn SH. Calcitriol in the treatment of postmenopausal osteoporosis. Am J Mod 1988; 84: 401–8.
Gallagher JC, Jerpbak CM, Jee WS, Johnson KA, DeLuca HF, Riggs BL. 1,25-dihydroxyvitamin D3: short- and long-term effects on bone and calcium metabolism in patients with postmenopausal osteoporosis. Proc Natl Acad Sci USA 1982; 79: 3325–9.
Ott SM, Chesnut CH. Calcitriol treatment is not effective in postmenopausal osteoporosis. Ann Intern Med 1989; 110: 267–74.
Gallagher JC, Goldgar D. Treatment of postmenopausal osteoporosis with high doses of synthetic calciferol. A randomized controlled study. Ann Internal Med 1990; 113: 649–55.
Christiansen C, Christiansen MS, Rodbro P, Hagen C, Transbol I. Effect of 1,25-dihydroxy-vitamin D3 in itself or combined with hormone treatment in preventing postmenopausal osteoporosis. Eur J Clin Invest 1981; 11: 305–9.
Falch IA, Odegaard OR, Finnanger AM, Matheson I. Postmenopausal osteoporosis: no effect of three years treatment with 1,25-dihydroxycholecalciferol. Acta Med Scand 1987; 221: 199–204.
Avenell A, Gillespie WJ, Gillespie LD, O’Connell DL. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev 2005; 3: CD000227.
Richy F, Schacht E, Bruyere O, Ethgen O, Gourlay M, Reginster JY. Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: A comparative meta-analysis. Calcif Tissue Int 2005; 76: 176–86.
Sairanen S, Kärkkäinen M, Tähtelä R, et al. Bone mass and markers of bone and calcium metabolism in postmenopausal women treated with 1,25-dihydroxyvitamin D (calcitriol) for four years. Calcif Tissue Int 2000; 67: 122–7.
Klein B, Kaufman JH, Isaacs J. Automated simultaneous calcium and phosphorus analysis. Clin Chem 1967; 13: 1071–8.
Matsuyama T, Ishii S, Tokita A, et al. Vitamin D receptor genotypes and bone mineral density. Lancet 1995; 345: 1238–9.
Graafmans WC, Lips P, Ooms ME, van Leeuwen JP, Pols HA, Uitterlinden AG. The effect of vitamin D supplementation on the bone mineral density of the femoral neck is associated with vitamin D receptor genotype. J Bone Miner Res 1997; 12: 1241–5.
Kobayashi N, Fujino T, Shirogane T, et al. Estrogen receptor alpha polymorphism as a genetic marker for bone loss, vertebral fractures and susceptibility to estrogen. Maturitas 2002; 41: 193–201.
Kurabayashi T, Tomita M, Matsushita H, et al. Association of vitamin D and estrogen receptor gene polymorphism with the effect of hormone replacement therapy on bone mineral density in Japanese women. Am J Obstet Gynecol 1999; 180: 1115–20.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zofkova, I., Hill, M. Long-term 1,25(OH)2 vitamin D therapy increases bone mineral density in osteopenic women. Comparison with the effect of plain vitamin D. Aging Clin Exp Res 19, 472–477 (2007). https://doi.org/10.1007/BF03324733
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03324733